Survodutide 10mg (Dual GLP-1 / Glucagon Agonist)⁠

Survodutide (10mg) is a cutting-edge, synthetic 29-amino-acid peptide engineered as a dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). In modern preclinical metabolic assay profiles, this dual-pathway mechanism provides a unique matrix for studying accelerated lipolysis alongside concurrent blood glucose balancing pathways.

Mechanistic & Cellular Target Channels

• GCGR Up-regulation: Activates hepatocyte cyclic AMP (cAMP) generation to simulate energy expenditure, oxygen consumption, and direct lipid tissue breakdown.
• GLP-1R Stabilisation: Mitigates downstream cellular hunger signaling pathways and regulates insulin dynamic shifts in a strictly glucose-dependent configuration.
• Structural Amending: Chemically structured to resist rapid degradation from dipeptidyl peptidase-4 (DPP-4) cleavage cascades, lengthening operational half-life parameters in vitro.

Reconstitution & Chemical Integrity Profiles

This asset is delivered as an ultra-pure, lyophilized white cake vacuum-sealed under an inert nitrogen blanket to eliminate ambient moisture artifacts. Reconstitution with 0.9% Sterile Bacteriostatic Water is optimal for structural recovery. Post-reconstitution fluids must be stored at a rigid 2–8°C boundary layer and protected completely from direct light or intense physical agitation.